{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:23Z","timestamp":1761101243127},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/bmt.2013.221","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T14:51:06Z","timestamp":1389624666000},"page":"513-518","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic transplantation after reduced-intensity conditioning with fludarabine\u2013CY for both indolent and aggressive lymphoid malignancies"],"prefix":"10.1038","volume":"49","author":[{"given":"M J","family":"Wondergem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F S","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O J","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B I","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J W M","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"BFbmt2013221_CR1","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic haematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2013221_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/sj.bmt.1700904","volume":"20","author":"EJ Dann","year":"1997","unstructured":"Dann EJ, Daugherty CK, Larson RA . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 1997; 20: 369\u2013374.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013221_CR3","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA . Nonablative allogeneic haematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-vs-host disease, and treatment-related mortality. Blood 2001; 98: 3595\u20133599.","journal-title":"Blood"},{"key":"BFbmt2013221_CR4","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BFbmt2013221_CR5","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","volume":"21","author":"P Corradini","year":"2007","unstructured":"Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316\u20132323.","journal-title":"Leukemia"},{"key":"BFbmt2013221_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","volume":"12","author":"R Rodriguez","year":"2006","unstructured":"Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Poplewel L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Biol Blood and Marrow Transplant 2006; 12: 1326\u20131334.","journal-title":"Biol Blood and Marrow Transplant"},{"key":"BFbmt2013221_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/annonc\/mdf010","volume":"13","author":"H Bertz","year":"2002","unstructured":"Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoetic stem cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135\u2013139.","journal-title":"Ann Oncol"},{"key":"BFbmt2013221_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/beha.2002.0223","volume":"15","author":"C Toze","year":"2002","unstructured":"Toze C, Barnett MJ . Allogeneic haemopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma. Best Pract Res Clin Haematol 2002; 15: 481\u2013504.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2013221_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2008","unstructured":"Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favourable long term survival after reduced-intensity alloSCT for multiple-relapse aggressive NHL. J Clin Oncol 2008; 27: 426\u2013432.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013221_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in relapsed, refractory and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008; 26: 211\u2013217.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013221_CR11","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","volume":"20","author":"AJ Barrett","year":"2006","unstructured":"Barrett AJ, Savani BN . Stem cell transplantation with reduced intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661\u20131672.","journal-title":"Leukemia"},{"key":"BFbmt2013221_CR12","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D . Consensus conference on acute GvHD. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013221_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers MED . Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215\u2013233.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013221_CR14","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"SP Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russel N, Ruiz de Elvira C et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation; an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310\u20134316.","journal-title":"Blood"},{"key":"BFbmt2013221_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","volume":"15","author":"M Hamadani","year":"2009","unstructured":"Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547\u2013553.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013221_CR16","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation for relapsed and refractory non-hodgkin lymphoma. Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BFbmt2013221_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","volume":"111","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R . Outcomes after allogeneic hematopoietic cell transplantation with non myeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446\u2013452.","journal-title":"Blood"},{"key":"BFbmt2013221_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","volume":"14","author":"P Armand","year":"2008","unstructured":"Armand P, Kim HT, Ho VT . Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418\u2013425.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013221_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2008","unstructured":"Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008; 27: 426\u2013432.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013221_CR20","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJW van Kampen","year":"2011","unstructured":"van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after autologous stem cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342\u20131348.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013221_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","volume":"111","author":"E Vellenga","year":"2008","unstructured":"Vellenga E, van Putten WJ, van\u2019t Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537\u2013543.","journal-title":"Blood"},{"key":"BFbmt2013221_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","volume":"114","author":"J Pidala","year":"2009","unstructured":"Pidala J, Anasetti C, Jim H . Quality of life after allogeneic stem cell transplantation. Blood 2009; 114: 7\u201319.","journal-title":"Blood"},{"key":"BFbmt2013221_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/asheducation.V2012.1.410.3798518","volume":"2012","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C . Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematology Am Soc Hematol Educ Program 2012; 2012: 410\u2013416.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2013221_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","volume":"14","author":"AJ Bloor","year":"2008","unstructured":"Bloor AJ, Thomson K, Chowdry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50\u201358.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013221_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/10428190310001623694","volume":"44","author":"DG Maloney","year":"2003","unstructured":"Maloney DG . Graft-vs-lymphoma effect in various histologies of non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 2003; 44: 99\u2013105.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2013221_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.beha.2004.08.017","volume":"18","author":"I Avivi","year":"2005","unstructured":"Avivi I, Goldstone AH . Conventional allograft and autograft in low grade lymphoma. Best Pract Res Clin Haematol 2005; 18: 113\u2013128.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2013221_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/leu.2010.187","volume":"24","author":"S Thepot","year":"2010","unstructured":"Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852\u20131858.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:06:32Z","timestamp":1648055192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFbmt2013221"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.221","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,13]]},"assertion":[{"value":"1 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}